NuVasive, Inc. (NUVA): Price and Financial Metrics

NuVasive, Inc. (NUVA)

Today's Latest Price: $44.43 USD

4.84 (-9.82%)

Updated Oct 30 4:00pm

Add NUVA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 142 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

NUVA Stock Summary

  • NUVA's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 442.53 -- higher than 92.38% of US-listed equities with positive expected earnings growth.
  • With a year-over-year growth in debt of 117.73%, Nuvasive Inc's debt growth rate surpasses 88.9% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for NUVA comes in at -39.21% -- higher than that of merely 11.53% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Nuvasive Inc are IART, HRC, CW, JCOM, and HUN.
  • NUVA's SEC filings can be seen here. And to visit Nuvasive Inc's official web site, go to

NUVA Stock Price Chart Interactive Chart >

Price chart for NUVA

NUVA Price/Volume Stats

Current price $44.43 52-week high $81.91
Prev. close $49.27 52-week low $28.55
Day low $44.13 Volume 3,907,700
Day high $47.28 Avg. volume 902,558
50-day MA $51.39 Dividend yield N/A
200-day MA $57.53 Market Cap 2.28B

NuVasive, Inc. (NUVA) Company Bio

NuVasive develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company was founded in 1997 and is based in San Diego, California.

NUVA Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$44.43$8.8 -82%

Below please find a table outlining a discounted cash flow forecast for NUVA, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Nuvasive Inc ranked in the 15th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 81.5%. In terms of the factors that were most noteworthy in this DCF analysis for NUVA, they are:

  • The compound growth rate in the free cash flow of Nuvasive Inc over the past 5.44 years is 0.02%; that's higher than only 23.85% of free cash flow generating stocks in the Healthcare sector.
  • Nuvasive Inc's weighted average cost of capital (WACC) is 10%; for context, that number is higher than 69.4% of tickers in our DCF set.
  • Nuvasive Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

BHC, MYGN, BSX, EHC, and IDXX can be thought of as valuation peers to NUVA, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

NUVA Latest News Stream

Event/Time News Detail
Loading, please wait...

NUVA Latest Social Stream

Loading social stream, please wait...

View Full NUVA Social Stream

Latest NUVA News From Around the Web

Below are the latest news stories about Nuvasive Inc that investors may wish to consider to help them evaluate NUVA as an investment opportunity.

Minimally Invasive Spinal Implant Market Global Opportunity Analysis and Industry Forecast 2020-2027 | Medtronic, DePuy Synthes, Zimmer Biomet, Stryker, NuVasive

Global Minimally Invasive Spinal Implant Market has been brewing up and influencing the international economy with respect to revenue, growth rate, sale, market share, and size. The Global Minimally Invasive Spinal Implant Market research report provides a rational explanation to

OpenPR | September 29, 2020

NuVasive Expands Precice Portfolio with First-of-its-Kind Plate for Pediatric Limb Lengthening and Reconstruction Procedures

SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the limited availability of the new Precice® Plate for use…

PR Newswire | September 9, 2020

Global Spinal Fusion Market 2015-2030: Key Trends, Regional & Competitive Insights, COVID-19 Impact -

DUBLIN--(BUSINESS WIRE)--The "Spinal Fusion (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to's offering. This market model discusses in detail the impact of COVID-19 on Spinal Fusion market for the year 2020 and beyond. Companies Mentioned Medtronic plc NuVasive Inc. DePuy Synthes Inc. Globus Medical Inc. Stryker Corp. Zimmer Biomet Holdings Inc. Lumbar fusions are the most common spinal fusion procedures

Business Wire | August 12, 2020

NuVasive EPS beats by $0.07, revenue in-line

NuVasive (NUVA): Q2 Non-GAAP EPS of -$0.40 beats by $0.07; GAAP EPS of -$0.98 misses by $0.19.Revenue of $203.61M (-30.3% Y/Y) in-line.Press Release...

Seeking Alpha | August 4, 2020

Will NuVasive (NUVA) Beat Estimates Again in Its Next Earnings Report?

NuVasive (NUVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Yahoo | July 29, 2020

Read More 'NUVA' Stories Here

NUVA Price Returns

1-mo -9.35%
3-mo -22.24%
6-mo -22.07%
1-year -37.05%
3-year -20.97%
5-year -10.10%
YTD -42.55%
2019 56.05%
2018 -15.27%
2017 -13.17%
2016 24.49%
2015 14.74%

Continue Researching NUVA

Here are a few links from around the web to help you further your research on Nuvasive Inc's stock as an investment opportunity:

Nuvasive Inc (NUVA) Stock Price | Nasdaq
Nuvasive Inc (NUVA) Stock Quote, History and News - Yahoo Finance
Nuvasive Inc (NUVA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8467 seconds.